References
- Cetin Y, Bullerman LB (2005): Cytotoxicity of Fusarium mycotoxins to mammalian cell cultures as determined by the MTT bioassay. Food Chem Toxicol 43: 755–764.
- Dilda PJ, Hogg PJ (2007): Arsenical-based cancer drugs. Cancer Treat Rev 33: 542–564.
- Gilbertson BP (2000): Creating value through innovation biotechnology in mining. Miner Process Extr Metall 109: 61–67.
- Li JE, Wu WL, Wang ZY, Sun GL (2002): Apoptotic effect of As2S2 on K562 cells and its mechanism. Acta Pharmacol Sinica 23: 991–996.
- Lu DP, Qiu JY, Jiang B, Wang Q, Liu KY, Liu YR, Chen SS (2002): Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood 99: 3136–3143.
- Lu DP, Wang Q (2002): Current study of APL treatment in China. Int J Hematol 76: 1316–1318.
- Mariko K, Kazunori K, Demidmaa T, Kenji I, Yasuji K, Kazuaki I, Terukatsu A (2002a): Inhibition by arsenic trioxide of human hepatoma cell growth. Cancer Lett 183: 147–153.
- Mariko K, Yukihiro A, Nobuko O, Kunio Y, Yoshinori N (2002b): Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophy Res Commun 291: 861–867.
- Prentis RA, Lis Y, Walker SR (1988): Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985). Br J Clin Pharmacol 25: 387–396.
- Rawlings DE (1998): Industrial practice and the biology of leaching of metals from ores. The 1997 Pan Labs Lecture. J Ind Microbiol Biotechnol 20: 268–274.
- Sand W, Gehrke T, Jozsa PG, Schippers A (2001): Biochemistry of bacterial leaching-direct vs. indirect bioleaching. Hydrometallurgy 59: 159–175.
- Shen ZX, Chen GQ, Ni JH (1997): Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89: 3354–3360.
- Silverman MP, Lundgren DG (1959): Studies on the chemoautotrophic iron bacterium Ferrobacillus ferrooxidans. I: An improved medium and harvesting procedure for securing high cells yields. J Bacteriol 77: 1117–1121.
- Siu KPY, Chan JYW, Fung KP (2002): Effect of arsenic trioxide on human hepatocellular carcinoma HepG2 cells: inhibition of proliferation and induction of apoptosis. Life Sci 71: 275–285.
- Wu JZ, Ho PC (2004): Speciation of inorganic and mentholated arsenic compounds by capillary zone electrophoresis with indirect UV detection: application to the analysis of alkali extracts of As2S2 (realgar) and As2S3 (orpiment). J Chromatogr A 1026: 261–270.
- Wu XH, Sun DH, Zhuang ZX, Wang XR, Gong HF, Hong JX, Lee FSC (2002): Analysis and leaching characteristics of mercury and arsenic in Chinese medicinal material. Anal Chim Acta 453: 311–323.
- Xu LY, Zeng FD, Ye HQ, Yang XL, Xu HB (2006): Antitumor activity of realgar nanoparticles and the distribution of arsenic in tissues of tumor-transplanted mice. Chin J New Drugs 15: 1845–1849.
- Zhang JH, Zhang X, Ni YQ, Yang XJ, Li HY (2007): Bioleaching of arsenic from medicinal realgar by pure and mixed cultures. Process Biochem 42: 1265–1271.
- Zhang P, Wang SY, Hu XH (1996): Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 17: 58–62.
- Zhen YY (2005). Chinese Pharmacopoeia, Part I. Beijing, Chemical Industry Press, pp. 236.